MDS to Dilute Ownership of MDS Proteomics: MDSP Says This Move is Part of Long-Term Plan | GenomeWeb

MDS Proteomics will soon have to find some new benefactors. MDS Inc., the parent company of instrument-maker MDS Sciex as well as MDS Proteomics, and owner of 87 percent of the struggling proteomics company, announced on Sept. 4 in its third-quarter earnings report that it “does not intend to make any further investments in MDS Proteomics.” This leaves the future of MDSP — which had no revenues and CA$8 million ($5.8 million) in net losses in Q3 2003 — open to speculation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.